CXCL8 and COVID-19: There is evidence of the benefit of antiretrovirals such as tenofovir against COVID-19.[13,14] In vitro and molecular docking studies suggest that tenofovir inhibits the Ribonucleic Acid (RNA)-dependent RNA polymerase of SARS-CoV-2.[38] This antiretroviral also has immunomodulatory effects, including decreased production of Interleukin (IL)-8 and IL-10,[39] cytokines that are associated with COVID-19 severity and mortality.[29]